You are here: Industry Insights > Janssen

News List

Vibalogics to Manufacture Clinical Material for Janssen contractpharma
May 15, 2020
CDMO to provide additional clinical trial material for COVID-19 vaccine candidate.
Janssen's CAR-T shows 100% response rate in multiple myeloma pharmatimes
May 14, 2020
Janssen has unveiled updated results from a mid-stage trial of its CAR-T therapy JNJ-4528, showing high rates of response in patients with relapsed or refractory multiple myeloma.
Janssen Receives FDA Approval of DARZALEX FASPRO with ENHANZE for Multiple Myeloma americanpharmaceuticalreview
May 07, 2020
Halozyme Therapeutics announced its collaborator Janssen Biotech has received approval from the U.S. Food and Drug Administration (FDA) for DARZALEX FASPRO™ (daratumumab hyaluronidase human- fihj).
SMC accepts Janssen’s ulcerative colitis drug Stelara for NHS use pharmaceutical-technology
April 17, 2020
Scottish Medicines Consortium (SMC) has accepted Janssen Pharmaceutical’s Stelara (ustekinumab) for use on the National Health Service (NHS) Scotland to treat moderately to severely active ulcerative colitis (UC) in adults.
Janssen seeks FDA approval for ponesimod in MS pharmaceutical-technology
March 20, 2020
Janssen Pharmaceutical has filed a new drug application with the US Food and Drug Administration (FDA) seeking approval for ponesimod to treat relapsing multiple sclerosis (MS) in adults.
J&J says no evidence darunavir works against coronavirus pharmaceutical-technology
March 18, 2020
Johnson and Johnson (J&J) have noted the lack of evidence that its HIV drug darunavir has antiviral activity against SARS-CoV-2, the novel coronavirus that causes Covid-19.
EMA PRIME status granted to Janssen’s inherited retinal disease gene therapy pharmatimes
March 06, 2020
Janssen has announced that the European Medicines Agency (EMA) has granted both PRIME (PRIority MEdicines) and Advanced Therapy Medicinal Product (ATMP) designations to its adeno-associated virus (AAV)-RPGR gene therapy product ...
Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular degeneration (AMD) and Diabetic Macular Oedema (DMO) prnasia
January 13, 2020
Exonate, an early stage biotechnology company, announced today that it has entered into a strategic collaboration agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Janssen Completes Acquisition of Investigational Bermekimab from XBiotech americanpharmaceuticalreview
January 06, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the completion of the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees ...
Janssen’s esketamine nasal spray approved in the EU pharmaceutical-technology
December 24, 2019
The European Commission (EC) has approved Johnson & Johnson subsidiary Janssen’s Spravato (esketamine) nasal spray for treatment-resistant major depressive disorder.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page